#APEXBr01: Rolditamig deuderuxtecan - ECD2 and ECD4 HER-2 ADC, DAR ~ 6

1st line cytotoxic for HER-2 low either TNBC or HR+, all PDL-1 neg

PFS in all HER-2 low pts: improved from 5.5 to 16.4 (HR 0.29)

OS trend HR 0.44

Heme tox most common, ILD 2.2% (no deaths)

#ESMO26